Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study
01. April 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK
31. Januar 2019 07:00 ET
|
Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (the “Company” or “Nash...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease
19. November 2018 07:00 ET
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...